[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"non-small-cell-lung-cancer-stage-iiib\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:non-small-cell-lung-cancer-stage-iiib":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,76,103],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100494040","phase-1-alectinib-pharmacokinetic-in-patients-with-nsclc-100494040",false,"NCT05713006","Alectinib Pharmacokinetic in Patients With NSCLC","A Phase I\u002FII Open-label Clinical Trial to Evaluate the Pharmacokinetics of Alectinib With Sequential Dose Escalation in Patients Diagnosed With ALK-rearranged Advanced Non-small Cell Lung Cancer.","Inclusion Criteria:\n\n* Both sexes\n* ≥ 18 years old\n* Pathologically confirmed diagnosis of NSCLC\n* Stage IIIB - IV by the American Joint Committee of Cancer Version 8.\n* Recurrent disease (at least 180 days from curative intent treatment)\n* ALK rearrangements tested by FDA-approved tests (IHQ or FISH)\n* Karnofsky PS scale ≥ 70%\n* Having received first-line treatment with anti-ALK inhibitors and one previous line of platinum-based chemotherapy.\n* Measurable disease as referred by RECIST version 1.1\n* Symptomatic brain metastases could receive prior treatment with radiotherapy or surgery for at least two weeks before treatment initiation.\n* Asymptomatic brain metastases could not receive local therapy before study inclusion.\n* Negative highly sensitive pregnancy test (serum or urine) within 72 days before first dose intervention.\n* Sexually active patients should use a contraceptive method with a failure rate of less than 1% per year.\n* Signed written informed consent\n* Adequate organ function (hematological, liver, and renal function)\n* Life expectancy of at least 12 weeks\n\nExclusion Criteria:\n\n* Carcinomatous meningitis confirmed by a positive CRL cytology or highly suspicious brain MRI.\n* Previous malignancies except for any carcinoma in-situ\n* Treatment with other anti-cancer therapy\n* Participating in other clinical trials in the former four weeks\n* Any other serious condition or uncontrolled active infection, altered mental status, or psychiatric condition that, in the investigator´s opinion, would limit the ability of an individual to meet the requirements of the study or which affects the interpretability of the results.\n* Active hepatitis virus infection (any serotype) or chronic infection with a potential risk of reactivation evaluated through a serological panel.\n* Active HIV infection.\n* Breastfeeding.","ALL","18 Years",{"count":19,"type":20},45,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This interventional study aims to determine the pharmacokinetics of orally administered alectinib with dose escalation from 300 mg to 600 mg twice daily in Mexican patients with advanced ALK-positive NSCLC.\n\nThe main question it aims to answer is: what will be the peak plasma concentrations of alectinib following sequential dose escalation (300, 450, and 600 mg BID) over nine weeks of pharmacokinetic evaluation (phase I) in Mexican patients with advanced ALK-rearranged NSCLC?\n\nIn phase I (on days 0, 21, and 42), oral alectinib will be administered twice per day (BID) to patients with ALK-positive NSCLC; starting with 300 mg BID in 21-day cycles and dose escalation in 150 mg increments until 600 mg BID. Blood samples will be taken before and after administration of each dose (on days 1, 22, and 43). The primary endopoints in phase I will be dose-limiting toxicity (DLT) and PK parameters (Cmax. maximum plasma concentration; Tmax: time to reach maximum concentration: AUC 1-12: area under plasma ocncentrations-time curve steady-state concentration). At the end of the last blood collection (at day 43), the evaluation of each cycle will be at 600 mg, and the participant will be discharged to continue their treatment on an outpatient basis. Phase one will finish on day 63 of the study.\n\nIn phase II, the chosen BID dose based on the phase I portion will be administrated until disease progression, development of unacceptable side effects, or withdrawal of consent. The primary endpoint in phase 2 is the overall response rate (ORR) per RECIST V.1.1.",[27,28],"Non-small Cell Lung Cancer Stage IIIB","ALK Gene Mutation",[30,31,32],"alectinib","positive-ALK","non small cell lung cancer","RECRUITING","2026-04-06",{"date":36,"type":37},"2026-04-08","ACTUAL",{"date":39,"type":37},"2022-05-01",{"date":41,"type":20},"2027-12-01",{"name":43,"class":44},"Instituto Nacional de Cancerologia de Mexico","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":56,"conditions":57,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100625854","phase-2-a-study-of-trastuzumab-deruxtecan-in-people-with-non-small-cell-lung-cancer-100625854","NCT07428044","A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer","A Phase II Trial of Neoadjuvant Trastuzumab Deruxtecan for Patients With Stage II-III HER2-Amplified or HER2-Mutated Non-Small Cell Lung Cancer (HERCULES)","Inclusion Criteria:\n\nPatients must meet the following criteria for study entry:\n\nNeoadjuvant Therapy\n\n* Signed informed consent form\n* Age ≥18 years\n* Able to comply with the study protocol, in the investigator's judgment\n* Pathologically documented NSCLC\n\n  o Stage II, IIIA, or selected IIIB, including T3N2 or T4 (by size criteria, not by mediastinal invasion), NSCLC (on the basis of the 8th edition of the AJCC NSCLC staging system)\n* Note: Patients may be enrolled on the basis of clinical stage, but documentation of nodal involvement by invasive mediastinal staging (e.g., endobronchial ultrasound or mediastinoscopy) is strongly encouraged\n* Molecular testing results on tissue and\u002For cfDNA from a CLIA-certified laboratory showing presence of a mutation or amplification (defined as ≥ 4 copies) of HER2. (See Appendix C for a list of known activating HER2 mutations in NSCLC. This is not intended to be a comprehensive list. The presence of any activating HER2 mutation is suitable.)of HER2including via Foundation Medicine testing on the LCMC4 LEADER protocol.\n* Molecular testing results used for patient eligibility should be obtained from a recent tumor biopsy (up to 6 months before enrollment). Alternatively, molecular testing results used to determine patient eligibility could have been obtained from a recent blood sample (up to 3 months before enrollment)\\]\n* Measurable disease as defined by RECIST v1.1 (exceptions may be made in cases of PERCIST-measurable disease \\[e.g., T0N2 cancer otherwise appropriate for induction therapy\\])\n* NSCLC must have a solid or subsolid appearance on CT scan and cannot have a purely ground-glass-opacity appearance. For subsolid lesions, the tumor size (i.e., clinical T stage) should be measured on the basis of the solid component only, exclusive of the ground-glass-opacity component\n* Evaluated by the attending surgeon before study enrollment to verify that the primary tumor and any involved lymph nodes are technically completely resectable and to verify that the patient is medically operable\n* Adequate pulmonary function to be eligible for surgical resection with curative intent\n\n  * Pulmonary function tests (PFTs) must be performed at screening and before surgery,in accordance with the preoperative calendar of events, and should include lung volumes, spirometry, and diffusion capacity\n  * Abnormal PFT results may be further evaluated with quantitative ventilation or perfusion scanning or cardiopulmonary exercise testing, at the discretion of the surgeon\n  * Postoperative percent predicted forced expiratory volume in 1 second and diffusion capacity must be ≥40% and\u002For preoperative maximal oxygen consumption (VO2 max) must be \\>15 mL\u002Fkg\u002Fmin\n  * It is acceptable to have the screening PFTs performed within 4 months of Cycle 1, Day 1, but they must be repeated before Cycle 1, Day 1, if clinically indicated\n  * The postinduction and preoperative PFTs must be performed at least 2 weeks after Cycle 2, Day 1\n* Echocardiogram demonstrating left ventricular ejection fraction (LVEF) ≥50% within 28 days before enrollment. If clinically indicated, patients with underlying ischemic or valvular heart disease should be evaluated preoperatively by a cardiologist\n* ECOG Performance Status of 0 or 1\n* Adequate hematologic and end-organ function, defined by the following laboratory results obtained within 14 days before the first dose of study treatment:\n\n  * Absolute neutrophil count ≥1500\u002FuL (granulocyte-colony stimulating factor administration is not allowed within 1 week before Cycle 1, Day 1)\n  * Platelet count ≥100,000\u002FuL (platelet transfusion is not allowed within 1 week before Cycle 1, Day 1)\n  * International normalized ratio or prothrombin time and either partial thromboplastin or activated partial thromboplastin time ≤1.5 × the upper limit of normal (ULN)\n  * Hemoglobin ≥9.0 g\u002FdL\n  * AST and ALT ≤3 × ULN\n  * Serum bilirubin ≤1.5 × ULN (up to 3 × ULN for patients with Gilbert syndrome)\n  * Creatinine clearance ≥30 mL\u002Fmin (as calculated using the Cockcroft-Gault equation)\n  * Serum albumin ≥2.5 g\u002FdL\n* Male and female participants of reproductive or childbearing potential must agree to use a highly effective form of contraception or avoid intercourse during and upon completion of the study and for at least 4.5 months after the last dose of the study drug. Methods considered to be highly effective forms of contraception include:\n\n  o Combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation:\n* Oral\n* Intravaginal\n* Transdermal\n\n  o Progestogen-only hormonal contraception associated with inhibition of ovulation:\n* Oral\n* Injectable\n* Implantable\n\n  * Intrauterine device\n  * Intrauterine hormone-releasing system\n  * Bilateral tubal occlusion\n  * Vasectomized partner\n  * Complete sexual abstinence, defined as refraining from heterosexual intercourse during and upon completion of the study and for at least 4.5 months after the last dose of the study drug. Periodic abstinence (calendar, symptothermal, post-ovulation methods) is not an acceptable method of contraception.\n  * Women of nonchildbearing potential, defined as premenopausal women with a documented tubal ligation or hysterectomy, or postmenopausal women, defined as those with 12 months of spontaneous amenorrhea (in questionable cases, a blood sample with simultaneous follicle-stimulating hormone \\>40 mIU\u002FmL and estradiol \\\u003C40 pg\u002FmL \\[\\\u003C147 pmol\u002FL\\] is confirmatory). Women on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods outlined for women of childbearing potential if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment. For most forms of HRT, at least 2 to 4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. After confirmation of their postmenopausal status, they can resume use of HRT during the study without the use of a contraceptive method\n* Male participants must not freeze or donate sperm starting at screening and throughout the study period and for at least 4.5 months after the final administration of the study drug. Preservation of sperm should be considered before enrollment in this trial\n* Female participants must not donate or retrieve for their own use ova from the time of randomization or enrollment and throughout the study treatment period and for at least 7 months after the final administration of the study drug\n* Participants should be willing and able to comply with protocol visits and procedures\n\nAdjuvant Therapy Adjuvant systemic therapy (i.e., platinum-based chemotherapy and\u002For immunotherapy) may be given to patients at the discretion of the treating physician.\n\nExclusion Criteria:\n\n* NSCLC that is clinically T4 by virtue of mediastinal organ invasion or stage IIIB by virtue of N3 disease\n* Patients who on initial assessment by treating thoracic surgeon, appear to require a total pneumonectomy to achieve a complete resection are ineligible for study enrollment\n* Any previous therapy for lung cancer, including chemotherapy, targeted therapy, immunotherapy, or radiotherapy, within 3 years\n* Previous lung cancer in remission for \\\u003C3 years, with the exception of minimally invasive adenocarcinoma or incidental typical carcinoid tumors\n* History of (noninfectious) ILD or pneumonitis that required steroids or current ILD or pneumonitis or suspected ILD or pneumonitis that cannot be ruled out by imaging at screening\n* Lung-specific intercurrent clinically significant illnesses including but not limited to any underlying pulmonary disorder (e.g., pulmonary emboli within 3 months of study enrollment, severe asthma, severe chronic obstructive pulmonary disease \\[COPD\\], restrictive lung disease, pleural effusion)\n* Any autoimmune, connective tissue, or inflammatory disorders (e.g., rheumatoid arthritis, Sjogren's, sarcoidosis) where there is documentation or suspicion of pulmonary involvement, at the time of screening. Full details of the disorder should be recorded in the eCRF for patients who are included in the study\n* Previous pneumonectomy (complete)\n* Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals\n* Active primary immunodeficiency, known uncontrolled active HIV infection, or active hepatitis B or C infection, such as those with serologic evidence of viral infection within 28 days of Cycle, 1 Day 1. Participants with past or resolved hepatitis B virus infection who are anti-HBc positive (+) are eligible only if they are HBsAg negative (-)\n* Corrected QT interval prolongation to \\>470 msec (women) or \\>450 msec (men) on the basis of the average of the screening triplicate 12-lead electrocardiogram (ECG)\n* Receipt of live, attenuated vaccine (mRNA and replication-deficient adenoviral vaccines are not considered attenuated live vaccines) within 30 days before the first dose of T-DXd.\n\nNote: Patients, if enrolled, should not receive live vaccine during the study and for up to 30 days after the last dose of the study drug\n\n* Known allergy or hypersensitivity to the study treatment or any of the study drug excipients\n* History of severe hypersensitivity reactions to other monoclonal antibodies\n* Substance abuse or any other medical conditions that would increase the safety risk to the participant or interfere with participation of the participant or evaluation of the clinical study,in the opinion of the investigator\n* Major surgical procedure within 28 days before Cycle 1, Day 1\n* Malignancies other than the disease under study within 3 years before Cycle 1, Day 1, with the exception of patients with a negligible risk of metastasis or death and with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, non-muscle invasive bladder cancer, localized prostate cancer treated surgically with curative intent, or ductal carcinoma in situ treated surgically with curative intent) or patients undergoing active surveillance per standard-of-care management (e.g., Rai stage 0 chronic lymphocytic leukemia, prostate cancer with Gleason score ≤6, and prostate-specific antigen \\[≤10 ng\u002FmL\\])\n* Treatment with an investigational agent for any condition within 4 weeks before Cycle 1, Day 1 (or within 5 half-lives of the investigational product, whichever is longer)\n* Medical history of myocardial infarction, symptomatic congestive heart failure (CHF; New York Heart Association class II-IV), unstable angina, or serious cardiac arrhythmia\n* Social, familial, or geographical factors that would interfere with study participation or follow-up\n* Concomitant medical condition that would increase the risk of toxicity, in the opinion of the investigator\n* Pregnant or lactating or intending to become pregnant during the study o Women of childbearing potential must have a negative serum pregnancy test result within 7 days before initiation of treatment",{"count":54,"type":20},14,[24],"The purpose of this study is to find out how many people with HER2-amplified or HER2-mutated non-small cell lung cancer (NSCLC) experience a decrease in tumor viability when they receive trastuzumab deruxtecan before routine surgery to remove tumors.",[58,59,60,61],"Non-Small Cell Lung Cancer","Non-small Cell Lung Cancer Stage II","Non-Small Cell Lung Cancer Stage IIIA","Non-Small Cell Lung Cancer Stage IIIB",[58,63,60,64,65,66],"Non-Small Cell Lung Cancer Stage II","Non-Small Cell Lung Cancer IIIB","Memorial Sloan Kettering Cancer Center","25-110","2026-02-17",{"date":69,"type":37},"2026-02-23",{"date":71,"type":37},"2026-02-13",{"date":73,"type":20},"2027-02-13",{"name":65,"class":44},10,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":21,"phases":86,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":45},"100581293","xingbai-ji-formula-combined-with-chemotherapy-and-sintilimab-in-metastatic-multi-target-mutation-negative-non-small-cell-lung-cancer-a-clinical-trial-100581293","NCT06848426","Xingbai Ji Formula Combined with Chemotherapy and Sintilimab in Metastatic Multi-Target Mutation-Negative Non-Small Cell Lung Cancer: a Clinical Trial","A Clinical Study of Xingbaiji Formula in Combination with Chemotherapy and Sintilimab As First-Line Treatment for Metastatic Multi-Target Mutation-Negative Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n1. Signed written informed consent.\n2. Age: 18-75 years, regardless of gender.\n3. Histologically or cytologically confirmed non-small cell lung cancer (NSCCC), including adenocarcinoma, squamous cell carcinoma, or large cell carcinoma, with negative EGFR, ALK, and ROS-1 mutations confirmed by next-generation sequencing (NGS). Stage IIIB-IV NSCLC as per AJCC 8th edition staging criteria (required evaluations: neck contrast-enhanced CT or ultrasound, chest contrast-enhanced CT, abdominal contrast-enhanced CT or ultrasound, brain contrast-enhanced MRI, bone scan, or whole-body PET\u002FCT).\n4. ECOG performance status ≤2 and life expectancy ≥3 months.\n5. Histologically or cytologically documented ineligibility for EGFR, ALK, or ROS-1 targeted therapies (written evidence required).\n6. At least one measurable lesion per RECIST v1.1. Lesions within prior radiation fields or post-local treatment may be selected if progression is confirmed.\n7. No prior systemic anti-tumor therapy for advanced disease. Adjuvant chemotherapy is permitted if ≥6 months have elapsed between recurrence and the last dose.\n\nExclusion Criteria:\n\n1. History of or concurrent other malignancies (excluding non-invasive tumors such as cured basal cell carcinoma of the skin, cervical carcinoma in situ, etc.);\n2. Individuals with allergic reactions to the Xingbaiji formula;\n3. Patients with mixed small cell lung cancer or those with a small cell lung cancer component;\n4. Severe mental illness or cognitive impairment that would impede compliance with study protocols or follow-up requirements;\n5. Pregnant or lactating women (a pregnancy test must be performed to exclude pregnancy; women of childbearing age must agree to use effective contraception during the study);\n6. Presence of any major illness or significant laboratory abnormalities that may interfere with receiving Xingbaiji formula, chemotherapy, or immunotherapy; 7Any other conditions deemed by the investigators to render participation in the trial inappropriate.","75 Years",{"count":85,"type":20},100,[87],"NA","Clinical Trial Protocol\n\nPrimary Objective:\n\nTo evaluate the efficacy of the Xingbaiji Formula combined with chemotherapy and Sintilimab as first-line therapy in patients with recurrent or metastatic Stage IIIB-IV EGFR\u002FALK\u002FROS-1 mutation-negative non-small cell lung cancer (NSCLC), using Objective Response Rate (ORR) of tumor lesions as the primary endpoint.\n\nSecondary Objectives:\n\nTo assess secondary endpoints including Progression-Free Survival (PFS), Quality of Life (QoL), immune-related indicators, and safety profile (e.g., incidence of adverse events), and to further evaluate the efficacy and safety of the combination therapy.\n\nRandomized Group Allocation:\n\nParticipants will be randomly assigned to two groups:\n\nControl Group\n\nRegimen for Advanced Non-Squamous NSCLC:\n\nDrugs and Dosage:\n\nSintilimab 200mg + Pemetrexed + Cisplatin\u002FCarboplatin via intravenous infusion, administered every 3 weeks (Q3W) for 4 cycles.\n\nAfter completion of 4 cycles, patients enter the maintenance phase: Sintilimab 200mg Q3W (up to 24 months) + Pemetrexed Q3W until disease progression, intolerable toxicity, death, or voluntary withdrawal.\n\nRegimen for Advanced Squamous NSCLC:\n\nDrugs and Dosage:\n\nSintilimab 200mg + Gemcitabine + Cisplatin\u002FCarboplatin via intravenous infusion, Q3W for 4-6 cycles.\n\nPost-treatment, patients receive Sintilimab 200mg Q3W maintenance until disease progression, intolerability, or completion of 2 years of Sintilimab therapy.\n\nExperimental Group Control Group Regimen + Xingbaiji Formula\n\nXingbaiji Formula Dosage:\n\n1. Granule No. 1: 10g\u002Fbag, dissolved in warm water. Administration: 1 bag orally, twice daily (morning and evening), after meals.\n2. Granule No. 2: 5g\u002Fbag, dissolved in warm water. Administration: 1 bag orally, twice daily (morning and evening), after meals. Treatment Duration: Both granules are taken concurrently with chemotherapy for 6 months, then discontinued.",[58,90,27,91,92],"Non-small Cell Lung Cancer Recurrent","Non-small Cell Lung Cancer Stage IV","Non-small Cell Lung Cancer Metastatic","NOT_YET_RECRUITING","2025-02-23",{"date":96,"type":37},"2025-02-27",{"date":98,"type":20},"2025-03-10",{"date":100,"type":20},"2028-01-31",{"name":102,"class":44},"Jiangxi Provincial People's Hopital",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":21,"phases":113,"briefSummary":114,"conditions":115,"keywords":119,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":4},"100549601","phase-2-osimertinib-and-etoposide-as-first-line-treatment-in-osimertinib-resistant-advanced-egfr-mutant-nsclc-100549601","NCT06436144","Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC","A Single-Center, Prospective, Single-Arm, Observational Study Evaluating the Efficacy and Safety of Osimertinib Combined With Etoposide as First-Line Treatment in Patients With Osimertinib-Resistant or -Insensitive, Advanced EGFR-Mutant Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n1. Age 18 to 79 years.\n2. Locally advanced (stage IIIB) or metastatic (stage IV) EGFR-mutant NSCLC.\n3. Harboring an EGFR sensitizing mutation (Exon 19 deletion or L858R).\n4. Received at least two cycles of first-line osimertinib treatment, with a best response of stable disease or slow progression.\n5. Life expectancy greater than 3 months.\n6. At least one measurable tumor lesion meeting the following criteria:\n\n1.No prior radiation therapy; 2.Measurable by chest CT or PET-CT, with a longest diameter ≥ 10 mm at baseline (short axis ≥ 15 mm for lymph nodes); 3.Amenable to accurate repeated measurements.\n\nExclusion Criteria:\n\n1. Currently receiving or planning to receive other anti-cancer therapies.\n2. Having contraindications to osimertinib or etoposide.\n3. Harboring known targetable osimertinib resistance mechanisms.","80 Years",{"count":112,"type":20},93,[24],"Osimertinib, though a standard first-line treatment for EGFR-mutant advanced NSCLC, shows primary resistance in 10-30% of patients, leading to disease progression within 3-4 months. This resistance is linked to co-mutations in genes like TP53, RB1, and PIK3CA, among others. Studies indicate that Topo II inhibitor Etoposide (VP-16) can reduce cell survival, enhance DNA damage, and delay resistance in Osimertinib-resistant cells, suggesting a potential combination therapy to manage resistance.This study is a single-center, prospective, single-arm study evaluating the efficacy and safety of osimertinib combined with etoposide as a first-line treatment in patients with osimertinib-resistant or -insensitive advanced non-small cell lung cancer (NSCLC). The study focuses on patients with advanced NSCLC (stage IIIB or IV) with EGFR-sensitive mutations who developed slow resistance to osimertinib and for whom secondary biopsy after resistance did not identify any therapeutic targets.",[116,117,118,91],"Non Small Cell Lung Cancer","EGFR Gene Mutation","Non Small Cell Lung Cancer Stage IIIB",[116,117,120],"Primary drug resistance of oxitinib","2024-05-28",{"date":123,"type":37},"2024-05-30",{"date":125,"type":20},"2024-06",{"date":127,"type":20},"2029-12",{"name":129,"class":44},"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University"]